These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 21840301)
1. Fisetin disposition and metabolism in mice: Identification of geraldol as an active metabolite. Touil YS; Auzeil N; Boulinguez F; Saighi H; Regazzetti A; Scherman D; Chabot GG Biochem Pharmacol; 2011 Dec; 82(11):1731-9. PubMed ID: 21840301 [TBL] [Abstract][Full Text] [Related]
2. Identification of absolute conversion to geraldol from fisetin and pharmacokinetics in mouse. Jo JH; Jo JJ; Lee JM; Lee S J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Dec; 1038():95-100. PubMed ID: 27810278 [TBL] [Abstract][Full Text] [Related]
3. Metabolism and pharmacokinetics of 3,3',4',7-tetrahydroxyflavone (fisetin), 5-hydroxyflavone, and 7-hydroxyflavone and antihemolysis effects of fisetin and its serum metabolites. Shia CS; Tsai SY; Kuo SC; Hou YC; Chao PD J Agric Food Chem; 2009 Jan; 57(1):83-9. PubMed ID: 19090755 [TBL] [Abstract][Full Text] [Related]
4. Liposomal encapsulation of the natural flavonoid fisetin improves bioavailability and antitumor efficacy. Seguin J; Brullé L; Boyer R; Lu YM; Ramos Romano M; Touil YS; Scherman D; Bessodes M; Mignet N; Chabot GG Int J Pharm; 2013 Feb; 444(1-2):146-54. PubMed ID: 23380621 [TBL] [Abstract][Full Text] [Related]
5. Selective inhibition of CYP2C8 by fisetin and its methylated metabolite, geraldol, in human liver microsomes. Shrestha R; Kim JH; Nam W; Lee HS; Lee JM; Lee S Drug Metab Pharmacokinet; 2018 Apr; 33(2):111-117. PubMed ID: 29454704 [TBL] [Abstract][Full Text] [Related]
6. Improved antiangiogenic and antitumour activity of the combination of the natural flavonoid fisetin and cyclophosphamide in Lewis lung carcinoma-bearing mice. Touil YS; Seguin J; Scherman D; Chabot GG Cancer Chemother Pharmacol; 2011 Aug; 68(2):445-55. PubMed ID: 21069336 [TBL] [Abstract][Full Text] [Related]
7. Nanoemulsion formulation of fisetin improves bioavailability and antitumour activity in mice. Ragelle H; Crauste-Manciet S; Seguin J; Brossard D; Scherman D; Arnaud P; Chabot GG Int J Pharm; 2012 May; 427(2):452-9. PubMed ID: 22387278 [TBL] [Abstract][Full Text] [Related]
8. Development of a liposomal formulation of the natural flavonoid fisetin. Mignet N; Seguin J; Ramos Romano M; Brullé L; Touil YS; Scherman D; Bessodes M; Chabot GG Int J Pharm; 2012 Feb; 423(1):69-76. PubMed ID: 21571054 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway by inositol pentakisphosphate results in antiangiogenic and antitumor effects. Maffucci T; Piccolo E; Cumashi A; Iezzi M; Riley AM; Saiardi A; Godage HY; Rossi C; Broggini M; Iacobelli S; Potter BV; Innocenti P; Falasca M Cancer Res; 2005 Sep; 65(18):8339-49. PubMed ID: 16166311 [TBL] [Abstract][Full Text] [Related]
10. Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties. Engel D; Nudelman A; Tarasenko N; Levovich I; Makarovsky I; Sochotnikov S; Tarasenko I; Rephaeli A J Med Chem; 2008 Jan; 51(2):314-23. PubMed ID: 18163551 [TBL] [Abstract][Full Text] [Related]
11. Comparison of pharmacokinetics of M1, M2, M3, and M4 after intravenous administration of DA-125 or ME2303 to mice and rats. New adriamycin analogues containing fluorine. Yoon EJ; Lee WI; Shim HJ; Lee SD; Kim WB; Yang J; Lee MG Biopharm Drug Dispos; 1996 Jul; 17(5):373-420. PubMed ID: 8830976 [TBL] [Abstract][Full Text] [Related]
12. Characterization of the major metabolites of flavone acetic acid and comparison of their disposition in humans and mice. Cummings J; Double JA; Bibby MC; Farmer P; Evans S; Kerr DJ; Kaye SB; Smyth JF Cancer Res; 1989 Jul; 49(13):3587-93. PubMed ID: 2731178 [TBL] [Abstract][Full Text] [Related]
13. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis. Naumova E; Ubezio P; Garofalo A; Borsotti P; Cassis L; Riccardi E; Scanziani E; Eccles SA; Bani MR; Giavazzi R Clin Cancer Res; 2006 Mar; 12(6):1839-49. PubMed ID: 16551869 [TBL] [Abstract][Full Text] [Related]
14. The transforming growth factor-beta family members bone morphogenetic protein-2 and macrophage inhibitory cytokine-1 as mediators of the antiangiogenic activity of N-(4-hydroxyphenyl)retinamide. Ferrari N; Pfeffer U; Dell'Eva R; Ambrosini C; Noonan DM; Albini A Clin Cancer Res; 2005 Jun; 11(12):4610-9. PubMed ID: 15958647 [TBL] [Abstract][Full Text] [Related]
15. Antiangiogenic properties of lupulone, a bitter acid of hop cones. Siegel L; Miternique-Grosse A; Griffon C; Klein-Soyer C; Lobstein A; Raul F; Stephan D Anticancer Res; 2008; 28(1A):289-94. PubMed ID: 18383859 [TBL] [Abstract][Full Text] [Related]
16. Dual Action of NAMI-A in inhibition of solid tumor metastasis: selective targeting of metastatic cells and binding to collagen. Sava G; Zorzet S; Turrin C; Vita F; Soranzo M; Zabucchi G; Cocchietto M; Bergamo A; DiGiovine S; Pezzoni G; Sartor L; Garbisa S Clin Cancer Res; 2003 May; 9(5):1898-905. PubMed ID: 12738748 [TBL] [Abstract][Full Text] [Related]
17. Ethyl pyruvate, an anti-inflammatory agent, inhibits tumor angiogenesis through inhibition of the NF-κB signaling pathway. Park SY; Yi EY; Jung M; Lee YM; Kim YJ Cancer Lett; 2011 Apr; 303(2):150-4. PubMed ID: 21333439 [TBL] [Abstract][Full Text] [Related]
18. Hispidulin, a small flavonoid molecule, suppresses the angiogenesis and growth of human pancreatic cancer by targeting vascular endothelial growth factor receptor 2-mediated PI3K/Akt/mTOR signaling pathway. He L; Wu Y; Lin L; Wang J; Wu Y; Chen Y; Yi Z; Liu M; Pang X Cancer Sci; 2011 Jan; 102(1):219-25. PubMed ID: 21087351 [TBL] [Abstract][Full Text] [Related]
19. Antiproliferative and antiangiogenic effects of the benzophenanthridine alkaloid sanguinarine in melanoma. De Stefano I; Raspaglio G; Zannoni GF; Travaglia D; Prisco MG; Mosca M; Ferlini C; Scambia G; Gallo D Biochem Pharmacol; 2009 Dec; 78(11):1374-81. PubMed ID: 19643088 [TBL] [Abstract][Full Text] [Related]
20. NM-3, an isocoumarin, increases the antitumor effects of radiotherapy without toxicity. Salloum RM; Jaskowiak NT; Mauceri HJ; Seetharam S; Beckett MA; Koons AM; Hari DM; Gupta VK; Reimer C; Kalluri R; Posner MC; Hellman S; Kufe DW; Weichselbaum RR Cancer Res; 2000 Dec; 60(24):6958-63. PubMed ID: 11156396 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]